Recital 7, Regulation (EU) 2026/140

In forcesince 22 Jan 2026

As regards trifloxystrobin in herbal infusions from flowers and in herbal infusions from leaves and herbs, the Authority concluded that the risk for consumers is unlikely despite considering that two residue field trials do not fully meet the independence criteria as defined in the Technical Guidelines [European Commission, 2020. Technical guidelines on data requirements for setting maximum residue levels, comparability of residue trials and extrapolation on residue data on products from plant and animal origin. SANTE/2019/12752, 23 November 2020.]. In view of the fact that the two concerned residue field trials did not overlap in time and that they were conducted at different sites, a risk management decision is made to consider these trials as independent. It is considered appropriate to set the requested MRLs for trifloxystrobin in herbal infusions from flowers and in herbal infusions from leaves and herbs at the level recommended by the Authority.